Eplerenone (INN) (IPA: ) is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is similar to spironolactone, though it may be more specific for the mineralocorticoid receptor and is specifically marketed for reducing cardiovascular risk in patients following myocardial infarction. It is marketed by Pfizer under the trade name Inspra.

Clinical use

---

Indications

Eplerenone is specifically indicated for the reduction of risk of cardiovascular death in patients with heart failure and left ventricular dysfunction within 3–14 days of an acute myocardial infarction, in combination with standard therapies.

Contraindications

Eplerenone is contraindicated in patients with hyperkalaemia, renal impairment, or severe hepatic impairment. The manufacturer of eplerenone also contraindicates concomitant treatment with ketoconazole, itraconazole or other potassium-sparing diuretics.

More on [ Eplerenone ]

Eplerenone - Twitter Search

Cardio: Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertensio http://url4.eu/hCdQ
MDLinx (Sandeep Pulim MD) Wed, 04 Nov 2009 09:16:39 -0000
Cardio: Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertensio http://url4.eu/hCdQ

Subscribe to Eplerenone RSS feed